BridgeBio Oncology Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule oncology programs for RAS and PI3Kα malignancies. Its 8-K reports cover material events such as leadership and board changes, compensatory arrangements, clinical-data press releases, and operating or financial results.
Proxy materials describe annual meeting matters, director elections, board classification, auditor ratification, and governance practices. The company’s filings also identify its common stock capital structure and formal disclosure categories for clinical and regulatory updates, governance, compensation, and public-company reporting obligations.
BridgeBio Oncology Therapeutics, Inc. (BBOT) Principal Accounting Officer Marc Cobo had 203 common shares withheld by the issuer on October 21, 2026, to satisfy tax withholding obligations connected with vesting of restricted stock units. The reported price was $2.68 per share; his direct holdings afterward were 13,812 shares.
Marc Cobo, BridgeBio Oncology Therapeutics, Inc.’s Principal Accounting Officer, had 126 common shares withheld by the issuer on October 1, 2026, at $3.94 per share to satisfy tax-withholding obligations tied to restricted stock unit vesting. He directly held 14,015 shares after the transaction.
BridgeBio Oncology Therapeutics, Inc.'s COO & Principal Financial Ofcr, Idan Elmelech, had 343 shares of common stock withheld by the issuer on October 1, 2026, to satisfy his tax-withholding obligations upon restricted stock unit vesting. The transaction price was $3.94 per share; his direct common-stock holdings afterward were 14,152 shares.
BridgeBio Oncology Therapeutics, Inc. (BBOT) President and CEO Pedro Beltran had 1,047 shares of common stock withheld on October 1, 2026, to satisfy tax withholding obligations connected with restricted stock unit vesting. The reported price was $3.94 per share, and his direct holdings afterward were 43,529 shares. No Rule 10b5-1 plan is reported.
BridgeBio Oncology Therapeutics, Inc. Chief Med & Dev Officer Ben Yong had 1,047 common shares withheld by the issuer on October 1, 2026, at a reported price of $3.94 per share to satisfy tax withholding obligations connected with restricted stock unit vesting. His directly held common stock position after the transaction was 43,529 shares.
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported that Principal Accounting Officer Marc Cobo received equity awards on September 10, 2026. He was granted options to buy 43,700 shares of common stock at $5.52 per share and 9,038 restricted stock units, while 203 shares were withheld to cover taxes on vesting.
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported new Phase 1 data for its KRAS-targeted pipeline and outlined a sharper strategic focus on select indications in KRAS‑mutant cancers. Lead asset BBO‑8520, a direct KRASG12C(ON/OFF) inhibitor, showed a 65% ORR in 2L+ KRASG12C inhibitor‑naïve NSCLC monotherapy and a 75% ORR at 500 mg once daily, and 53% ORR across doses, when combined with pembrolizumab in KRASG12C inhibitor‑experienced NSCLC.
The company is prioritizing BBO‑8520 plus pembrolizumab in 2L+ KRASG12C inhibitor‑experienced NSCLC and combinations of BBO‑11818 (pan‑KRAS ON/OFF) and BBO‑10203 (3Kα breaker) with or without standard of care in KRAS‑mutant colorectal and pancreatic cancers, while deprioritizing BBO‑8520 in 1L NSCLC and BBO‑10203 in breast cancer. BBOT reported $344.1 million in cash, cash equivalents and marketable securities as of June 30, 2026 and projects its cash runway will fund operations into 2028, including full Phase 1 development of all three programs, with multiple data readouts expected through mid‑2027.
BridgeBio Oncology Therapeutics, Inc. (BBOT) has filed a shelf registration statement allowing it to offer up to $500,000,000 of common stock, preferred stock, debt securities, warrants and units from time to time, and a related sales agreement prospectus for an at-the-market program covering up to $200,000,000 of common stock through Leerink Partners and Cantor Fitzgerald.
The company’s common stock trades on the Nasdaq Global Market under the symbol BBOT and closed at $8.80 per share on August 31, 2026; shares outstanding were 80,115,002 as of June 30, 2026. BBOT states that any net proceeds from offerings will be used for general corporate purposes, including research and development and clinical advancement of its oncology pipeline, working capital and other corporate needs. BBOT is an emerging growth company and smaller reporting company and therefore uses scaled disclosure and extended transition periods for new accounting standards.